Clinical Trial Update: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update assessing the efficacy and safety of ABT-126 in individuals with mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABT-126

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED